new logo.jpg
Immutep successfully completes institutional placement and institutional component of entitlement offer
June 05, 2024 06:00 ET | Immutep Limited
Sydney, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ACN 009 237 889 (ASX: IMM, NASDAQ: IMMP) (Immutep or the Company) is pleased to announce the successful completion of its...
new logo.jpg
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial
June 02, 2024 20:38 ET | Immutep Limited
Phase III collaboration will evaluate efti in combination with KEYTRUDA, MSD’s anti-PD-1 therapy, and standard chemotherapy in first-line non-small cell lung cancer (1L NSCLC)TACTI-004 Phase III trial...
new logo.jpg
Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024
May 15, 2024 08:00 ET | Immutep Limited
Media Release Confirmed complete response in a patient with metastatic breast cancer refractory to several lines of therapy achieved during combination treatment with 90mg efti and paclitaxelOngoing...
new logo.jpg
Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma
May 02, 2024 08:00 ET | Immutep Limited
Media Release Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging initial efficacy data in EFTISARC-NEO Phase II trialFour of six...
new logo.jpg
Immutep Quarterly Activities Report Q3 FY24
April 29, 2024 08:00 ET | Immutep Limited
Media Release First clinical data from the safety lead-in of AIPAC-003 in metastatic breast cancer shows 90mg dosing of efti safe and well tolerated: 50% overall response rate, including one patient...
new logo.jpg
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
April 24, 2024 08:00 ET | Immutep Limited
Media Release Data from efti in combination with KEYTRUDA® in first line head and neck squamous cell carcinoma patients who do not express PD-L1 (TACTI-003, Cohort B) shows a preliminary 26.9%...
new logo.jpg
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761
April 18, 2024 08:00 ET | Immutep Limited
Media Release Centre for Human Drug Research (CHDR) will conduct Phase I trial to evaluate IMP761, a first-in-class LAG-3 agonist antibody designed to restore balance to the immune system and address...
new logo.jpg
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
April 17, 2024 08:00 ET | Immutep Limited
SYDNEY, AUSTRALIA, April 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3...
new logo.jpg
Immutep Announces First Clinical Data from 90mg Dosing of Efti
March 05, 2024 08:00 ET | Immutep Limited
Data from the safety lead-in of the AIPAC-003 trial shows 90mg efti in combination with paclitaxel is safe and well toleratedEncouraging initial efficacy in six metastatic breast cancer patients, who...
new logo.jpg
Immutep Quarterly Activities Report Q2 FY24
January 30, 2024 08:00 ET | Immutep Limited
Media Release Excellent clinical data reported from TACTI-002 Phase II trial, including median Overall Survival of 35.5 months in first line non-small cell lung cancer (1L NSCLC) patients expressing...